Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × lazertinib × Clear all

NCT05498428 2026-04-13

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-04-13

COCOON

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-04-13

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06268210 2026-02-09

NeoLazer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05786430 2026-01-27

LUCAS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05338619 2023-09-01

PLATINUM

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06020989 2023-09-01

CHAMELEON

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05167851 2021-12-22

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung